The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

The present invention relates to compounds of formula (A), (A-I), (A-II), (A-III), (B), (B-I), (C), (D), (E), (E-I), (F), (G), (H), (J), and (K), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer, including prostate cancer.

The present invention relates to compounds of formula (A), (A-I), (A-II), (A-III), (B), (B-I), (C), (D), (E), (E-I), (F), (G), (H), (J), and (K), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer, including prostate cancer.

The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof. ##STR00001##

This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.

This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.

The invention relates to carboxamide-pyrimidine derivatives of the general formula I,

##STR00001##

or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Biochemically active PASTA kinase inhibitors which exploit subtle structural differences between human kinases and bacterial PASTA kinases to improve specificity and inhibitor activity. The disclosed kinase inhibitors have the general formula:

##STR00001##

wherein: R.sub.1=Me, Et, n-Pr, —CH.sub.2CH.sub.2OH, —CH.sub.2CH.sub.2OP(O)(OH).sub.2, —CH.sub.2CH.sub.2NMe.sub.2; R.sub.2=H, Me, Et, o-Pr, i-Pr, CF.sub.3, Cl, OMe; R.sub.3=H, Me, NHMe, NHBn, Cl, NO.sub.2OMe, F, CN; and Ar=

##STR00002##

Biochemically active PASTA kinase inhibitors which exploit subtle structural differences between human kinases and bacterial PASTA kinases to improve specificity and inhibitor activity. The disclosed kinase inhibitors have the general formula:

##STR00001##

wherein: R.sub.1=Me, Et, n-Pr, —CH.sub.2CH.sub.2OH, —CH.sub.2CH.sub.2OP(O)(OH).sub.2, —CH.sub.2CH.sub.2NMe.sub.2; R.sub.2=H, Me, Et, o-Pr, i-Pr, CF.sub.3, Cl, OMe; R.sub.3=H, Me, NHMe, NHBn, Cl, NO.sub.2OMe, F, CN; and Ar=

##STR00002##